PharmacoEconomics & Outcomes News 251 - 26 Feb 2000 Cost drivers in type 2 diabetes Hospitalisation and pharmacotherapy are the main cost drivers in patients with type 2 diabetes mellitus in a managed-care setting, report investigators from Procter & Gamble Pharmaceuticals and Merck-Medco Managed Care, L.L.C., US. Using 1995 medical and pharmacy claims data from the Hawaii Medical Service Association for 5171 patients (aged < 65 years) with type 2 diabetes, the investigators estimated that hospitalised patients incur direct medical costs (from the payer perspective) that are about 424% higher than those incurred by patients not using inpatient care. Insulin + oral antidiabetics major cost driver The study also showed that medical costs were about 278% higher for patients who received both insulin and oral antidiabetics. For patients receiving insulin alone or oral antidiabetics alone, the marginal cost contributions were 137 and 125%, respectively. Dialysis services were also identified as a major cost driver, with a marginal cost contribution of 153%. Furthermore, patients with neurological disorders, those with renal disorders and those with any comorbidity combination also incurred much higher costs than those without such conditions (marginal cost contributions of 114, 113 and 97%, respectively). Bhattacharyya SK, et al. Medical costs of managed care in patients with type 2 diabetes mellitus. Clinical Therapeutics 21: 2131-2142, Dec 1999 800813417 1 PharmacoEconomics & Outcomes News 26 Feb 2000 No. 251 1173-5503/10/0251-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

Cost drivers in type 2 diabetes

Download PDF Report

Upload
phungkhuong
View
212
Download
0

Embed Size (px)

Citation preview

PharmacoEconomics & Outcomes News 251 - 26 Feb 2000

Cost drivers in type 2 diabetesHospitalisation and pharmacotherapy are the main

cost drivers in patients with type 2 diabetes mellitus in amanaged-care setting, report investigators from Procter& Gamble Pharmaceuticals and Merck-Medco ManagedCare, L.L.C., US.

Using 1995 medical and pharmacy claims data fromthe Hawaii Medical Service Association for 5171patients (aged < 65 years) with type 2 diabetes, theinvestigators estimated that hospitalised patients incurdirect medical costs (from the payer perspective) thatare about 424% higher than those incurred by patientsnot using inpatient care.

Insulin + oral antidiabetics major cost driverThe study also showed that medical costs were about

278% higher for patients who received both insulin andoral antidiabetics. For patients receiving insulin alone ororal antidiabetics alone, the marginal cost contributionswere 137 and 125%, respectively.

Dialysis services were also identified as a major costdriver, with a marginal cost contribution of 153%.Furthermore, patients with neurological disorders, thosewith renal disorders and those with any comorbiditycombination also incurred much higher costs than thosewithout such conditions (marginal cost contributions of114, 113 and 97%, respectively).Bhattacharyya SK, et al. Medical costs of managed care in patients with type 2diabetes mellitus. Clinical Therapeutics 21: 2131-2142, Dec 1999 800813417